RxAnte is excited to attend this year’s the 15th Annual World Health Care Congress and participate as a speaker and exhibitor. RxAnte President and CEO Josh Benner, PharmD, ScD, is presenting on our experience leveraging a unique value-based contract development process, in which RxAnte acts as an impartial third party between health plans and pharmaceutical companies, offering credible and objective data analysis to help all parties make the most out of medicines.
On Tuesday, May 1st Josh is participating on a keynote panel to discuss value-based contracting and the quest for affordability in drug pricing. He’ll be joined by his fellow industry experts, Robert E. Andrews, Chief Executive Officer, Health Transformation Alliance; Azmi Nabulsi, MD, Deputy Chief Medical and Scientific Officer, Takeda; and Enrique A. Conterno, Senior Vice President, Eli Lilly and Company; President, Lilly Diabetes; President, Lilly USA.
Today’s healthcare environment shows most players are moving toward the value model, but with such a change in the marketplace comes new challenges and solutions in ensuring increased affordability and transparency between plans and manufacturers. The panel is discussing cross-sector initiatives to price prescription drugs based on value and outcomes, as well as the effectiveness of new value-based contracts between key stakeholders, including pharmaceutical companies, pharmacy benefit managers, employers, and health plans.
Drug Pricing: Value-Based Contracting and the Quest for Affordability, from 3:50pm – 4:50 pm on Tuesday, May 1, in the Thurgood Marshall Ballroom. To talk with us about our medication adherence and drug value solutions at this year’s WHCC, please visit our booth #411.